Pacira Reports Record Fourth Quarter and Full Year Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharma (PCRX) Tops Q4 EPS by 19c
February 28, 2019 8:04 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.47, $0.19 better than the analyst estimate of $0.28. Revenue for the quarter came in at $95.1 million versus the consensus estimate of $93.69 million.
Pacira announces its full year 2019 financial guidance as follows. Pacira expects:
EXPAREL net product... More